Ikena Oncology, INC Schedule 13D activist filings

OrbiMed Advisors and affiliated entities increased their beneficial ownership in ImageneBio, Inc. following participation in a 2026 private placement of pre-funded warrants.

Omega Fund VI, L.P. and associated entities have reported beneficial ownership of 8.4% of ImageneBio, Inc. common stock following recent financing.

OrbiMed Advisors and its affiliates have updated their beneficial ownership in ImageneBio, Inc. to 6.92% after a 1-for-12 reverse stock split and a Private Investment in Public Equity (PIPE) transaction, which included a significant share purchase by an OrbiMed entity at a notably lower price than other PIPE investors.

Atlas Venture funds report a significant dilution of their beneficial ownership in ImageneBio, Inc. to 3.6% following the company's merger with Inmagene Biopharmaceuticals and a 1-for-12 reverse stock split.

BML Investment Partners and Braden M. Leonard have significantly reduced their beneficial ownership in Ikena Oncology, Inc., ceasing to be a 5% holder after recent share sales.

OrbiMed Advisors and its affiliated entities have increased their beneficial ownership limitation in Ikena Oncology, Inc. to 19.99%, leading to the conversion of over 6 million non-voting shares into common stock.

BML Capital Management, holding an 8.5% stake in Ikena Oncology, Inc., has publicly declared its opposition to the proposed reverse merger with Inmagene Biopharmaceuticals, advocating instead for a wind-down of operations and cash return to shareholders.